Neuren Pharmaceuticals (ASX:NEU) Total Equity: A$338.45 Mil (As of Dec. 2025)


ASX:NEU Neuren Pharmaceuticals Ltd ASX:NEU
54 GF Score
Price A$17.75
GF Value A$6.08
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Neuren Pharmaceuticals Total Equity?

Neuren Pharmaceuticals ASX:NEU +6.93% 54 Total Equity is A$338.45 Mil as of Dec. 2025. GuruFocus rates ASX:NEU with a GF Score™ of 54/100 and a GF Value™ of A$6.08 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Neuren Pharmaceuticals's total equity for the quarter that ended in Dec. 2025 was A$338.45 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Neuren Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Neuren Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuren Pharmaceuticals Total Equity Chart

Neuren Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.25 41.59 205.21 363.90 338.45

Neuren Pharmaceuticals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 205.21 219.15 363.90 323.27 338.45
ASX:NEU
54GF Score
Neuren Pharmaceuticals Ltd ASX:NEU
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neuren Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Neuren Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=342.859-4.405
=338.45

Neuren Pharmaceuticals's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=342.859-4.405
=338.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of A$338.45 Mil mean?
Neuren Pharmaceuticals (ASX:NEU) has a Total Equity of A$338.45 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Neuren Pharmaceuticals and its competitors.
Is Neuren Pharmaceuticals' Total Equity too high?
Neuren Pharmaceuticals' current Total Equity is A$338.45 Mil. Overall, Neuren Pharmaceuticals has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' Total Equity compare to VRTX and REGN?
Neuren Pharmaceuticals' Total Equity of A$338.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Neuren Pharmaceuticals and its competitors. Neuren Pharmaceuticals's current Total Equity is A$338.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (ASX:NEU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$6.08, compared to a current price of A$17.75 — trading 191.9% above its estimated fair value. The current Total Equity is A$338.45 Mil. Neuren Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Neuren Pharmaceuticals (ASX:NEU), the current Total Equity is A$338.45 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neuren Pharmaceuticals (ASX:NEU) Overvalued in 2026?

Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued. The current stock price of A$17.75 is trading 191.9% above its estimated GF Value™ of A$6.08. GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ASX:NEU:

  • Total Equity: A$338.45 Mil
  • GF Value™: A$6.08 vs. price of A$17.75 (191.9% above fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the ASX:NEU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neuren Pharmaceuticals Business Description

Other Exchanges NURPF:USANK9:Germany
Address 117 Camberwell Road, Suite 1.01, Hawthorn East, Melbourne, VIC, AUS, 3123
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
54GF Score

Get the complete analysis for ASX:NEU

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$17.75
Price
A$6.08
GF Value